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Phenotypic and Genotypic Analyses of Genetic Skin
Disease through the Online Mendelian Inheritance in
Man (OMIM) Database
Jamison D. Feramisco1, Ruslan I. Sadreyev2,5, Mitzi L. Murray3,5, Nick V. Grishin2 and Hensin Tsao4
Despite unprecedented gains in genomic technologies and genotype resolution, there remain tremendous
challenges in our ability to capture disease ‘‘phenomes.’’ We propose a previously unreported method for
deconvolving human disease into elemental features, thereby creating a third space that interacts with both the
disease and genotypic spaces. Using cutaneous and noncutaneous clinical findings available through Johns
Hopkins University’s Online Mendelian Inheritance in Man (OMIM) database, we set out to deconstruct genetic
skin disease (GSD) into its various components, to more fully explore the relationship between these features
within the complex phenotypic space and to characterize the genotypic space within which these disorders
exist. Using OMIM, we defined the current state of GSD as including 560 distinct disorders associated with 501
unique protein-encoding genes. The most common elemental skin features included cornifying, erosive, and
hair/nail phenotypes, and the most common systemic features included those associated with developmental,
musculoskeletal, and neurological systems. As a proof of principle, we focused on a single skin feature— cafe´-
au-lait macules—and partitioned the disease space into hierarchical groupings on the basis of this finding.
Finally, functional analyses among GSD loci were mapped back to skin features, providing insights into
pigmentary and auditory features. Phenotypic deconvolution provides a framework for analyzing medical
disorders and can aid in the organization and elucidation of biological mechanisms related to human disease.
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INTRODUCTION
The process of defining disease and clinical syndromes is one
of convolution, that is, a large number of systemic features
are viewed in coherence as a single disease entity or a small
set. Although efficient for medical practice, this synthetic
approach obscures much of the phenotypic signal that could
be codified through astute clinical observation. As the human
genome becomes unraveled, one of the central problems in
clinical research is the systematic search for relationships
between disease genotypes and clinical phenotypes. Despite
tremendous gains in genomic technologies and high-
throughput sequencing, our ability to articulate the disease
‘‘phenome’’ is still in its infancy. One could argue that a
major barrier to large-scale phenomic research is the
established practice of convoluting phenotypes in medicine.
Most diseases are bucketed into organ-specific bins and are
thus not subject to systematic capture or global analysis. The
organ-selective nature of most medical education and
delivery conspires to limit the appreciation of disease
annotation in nondominant organs.
With these challenges in mind, we set out to deconvolve
disease phenotypes into a set of elemental features, that is, a
process we term ‘‘phenotype deconvolution.’’ As shown in
Figure 1, the disease space is represented by the set of all
defined medical disorders (d1, d2, d3, y, dN). The genotypic
space is represented by the collection of all disease-related
variants (g1, g2, g3, y, gN), and it interacts with the disease
space once causative variants have been identified. We
propose a third space, defined by constituent features (f1, f2,
f3, y, fN), which comprises the set of historical observations,
symptoms, or physical findings related to the specific disease.
Highly related disorders (Figure 1, d1 and d2) often share very
similar features (f1, f2, f3) that reflect a common genetic cause
(g1) or genetic lesions that interact on the same pathway
(g1 and g2). Within this third space, individual features may
be shared by numerous diseases that may not be obviously
connected in known genetic relationships (for example, f6).
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We propose that, if the deconvolution is thorough and
systematic, these features may provide, to our knowledge,
previously unknown insights within the disease space
(for example, d3, d5, d7, d8) and possibly new associations
among their respective genetic loci (for example, g3, g5, g7,
g8). It is also possible to define every disease as a point in an
N-dimensional space, characterized by the set of N features.
Within this framework, undisclosed relationships between
diseases may be revealed through hierarchical clustering of
absent or present (that is, 1 or 0) data or even quantitative
measures. We designate the process of feature clustering
and functional networking as type 1 and type 2 analyses,
respectively.
As a proof of concept, we deconvolved a set of genetic
skin diseases (GSDs) for which the molecular bases have
been established. We extracted disease features from one of
the largest ongoing collections of clinical annotation and
genotypes: the Online Mendelian Inheritance in Man (OMIM)
database. From the outset, we recognized the limitations and
accuracy of any large-scale disease database; however, few
extant efforts have the breadth of disease and genetic
information that is embodied by OMIM.
RESULTS
Features of GSD
We first deconvolved the GSDs into cutaneous and extra-
cutaneous features as outlined in Figure 2 and Table 1; the
entire dataset is available in Supplementary Table S1
(CGenDerm Database). For the 688 disease units, there were
a total of 1,640 cutaneous features and 2,551 extracutaneous
features, for an average of 2.38 cutaneous and 3.71
extracutaneous features, respectively, per disease unit. Our
analysis indicated that, of the 560 unique diseases defined in
the space for all GSDs, only 60 are ‘‘pure genodermatoses,’’
exhibiting skin phenotypes without systemic manifestations.
This is not surprising, as few genes are likely to function only
in a skin-restricted manner.
We next focused on the skin features associated with the
GSDs. Figure 3 shows a ranking of cutaneous features by
class and subclass (Figure 3a and b). Individually, ichthyosis/
scaling (group 1D) and other abnormal features of cornification
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Figure 1. Disease deconvolution. There are three interactive spaces. The
disease phenotype space is composed of all known human disease (d1ydN).
The feature space is composed of all possible clinical histories, symptoms,
and findings (f1yfN). The genotype space is defined by all variants at loci that
contribute to disease (g1ygN). Human diseases can be deconvolved into
individual features all representing a single dimension in an N-dimensional
space; although most clinical features can be reduced to present or absent
data, quantitative categorical data can also be included. Type 1 analysis is
aimed at identifying subgroups of diseases that share similar features on a
global level. Organ-specific disease management often minimizes the
phenotypes at other nondominant organ sites. For instance, the recent
recognition that psoriatic patients are at significant risk for ischemic heart
disease (Gelfand et al., 2006) emerged with a more careful scrutiny of
psoriatic features. Type 2 analysis is aimed at identifying genetic interactions
that may be detected through individual or groups of features. For instance,
hair loss is a feature in many diseases that may not be skin focused. An
understanding of the genetic bases for these diseases can in fact contribute to
a greater understanding of hair development.
Search OMIM
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688 Total
disease entries
560 Unique disease:
CGenDerm database
138 Unique disease entries with
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exclude from CGenDerm database
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Figure 2. OMIM analysis and the CGenDerm database. When OMIM was
searched using the term ‘‘skin,’’ 2,319 entries were identified. Of these, 826
entries represented diseases with a known genetic mechanism and 313
represented ‘‘orphan’’ genodermatoses. There were 560 unique genetic skin
diseases, from which the CGenDerm database was generated.
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Table 1. CGenDerm phenotype classification scheme
(a) Dermatological phenotype
1 Cornification
A Xerosis (15; 14)
B Hyperkeratosis—not otherwise specified (63; 66)
C Hyperkeratosis—Acanthosis nigricans type (13; 14)
D Hyperkeratosis—Icthyosis/scaling type (36; 36)
2 Pigmentation
A Hyperpigmentation (76; 69)
B Cafe´-au-lait (22; 25)
C Hypopigmentation (41; 39)
D Poikiloderma (8; 8)
E Nevi (13; 12)
3 Vascular
A Telangiectasis (17; 17)
B Ecchymosis/purpura/petechiae (30; 30)
C Edematous/swelling/angioedema (40; 40)
D Vasculitis (5; 4)
E Livedo reticularis (3; 3)
F Hemangioma/angiokeratoma/vascular malformations (24; 27)
4 Connective tissue
A Laxity (26; 23)
B Atrophy/aplasia/thin/fragile skin (50; 44)
C Sclerodermoid/thick skin/velvety (24; 27)
D Other/wound healing/calcification/amyloid disposition/
granuloma/texture/keloid (29; 29)
E Lipodystrophy (12; 12)
5 Neoplasms
A Benign (67; 60)
B Malignant (22; 21)
C Verrucous (5; 6)
6 Blistering diseases (37; 31)
7 Erosions/ulcerations (23; 28)
8 Photosensitivity/porphyrin disorders (25; 23)
9 Premature aging (3; 3)
10 Immune mediated
A Immune deficiency/recurrent infections (36; 37)
B Autoimmune (4; 3)
C Hypersensitivity/atopic dermatitis (14; 16)
Table 1. Continued
11 Hair/Nails
A Alopecia/hypotrichosis (83; 80)
B Hypertricosis/hirsuitism (31; 46)
C Structural (66; 68)
D Nails (87; 82)
12 Metabolic mediated (including jaundice, xanthomas) (43; 45)
13 Sweat disorders
A Hypo/anhidrosis (19; 16)
B Hyperhidrosis (19; 26)
14 Dermatitis/erythema (61; 73)
15 Acne (8; 9)
16 Mucosal (35; 38)
17 Aberrant landmark/structural/topography (including dimpling, loss of
skin folds, extra skin folds, pre-auricular pits, accessory nipples, single
palmar crease, fistulas) (87; 88)
18 Urticaria (7; 9)
(b) Systemic phenotype
A–Auditory (Deafness) (93; 94)
B–Biochemical/Metabolic (75; 78)
C–Cardiovascular
1. Congenital malformations (51; 50)
2. Other (78; 93)
D–Development/growth
1. Dysmorphology (132; 125)
2. Abnormal growth (196; 195)
E–Endocrine (73; 67)
G–Gastrointestinal
1. Congenital malformations (25; 25)
2. Other (114; 117)
H–Hematological (89; 90)
I–Immune system (70; 72)
L–Lymphatic (9; 7)
Table 1 continued on the following page
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(group 1B) represent the most common cutaneous features in
GSD. Hair/nail and cornification abnormalities represent
the two largest groups of cutaneous features. Many GSDs
have multiple cutaneous features. For instance, Kindler
syndrome (OMIM 173650) has features of hyperkeratosis,
dyspigmentation, blister formation, and nail dystrophy.
Although all these findings may be explained as direct or
indirect consequences of KIND1 mutations, we separately
annotated these features so as to delineate the phenotypic
relationship between Kindler syndrome and other conditions
with hyperkeratosis or blister formation. As shown in Figure
3c, most conditions have a single dominant cutaneous
feature; however, there are many diseases with multiple
distinct cutaneous features.
Fine dissection of extracutaneous findings represents a
formidable challenge because disease variation within any
one organ system may be as great as that observed only for
skin. With that caveat, we stratified the individual extra-
cutaneous features into broad classes (Table 1). Figure 4
shows a ranking of extracutaneous features associated with
the 688 composite phenotypes. In aggregate, developmental
anomalies (group D) represent the most common class of
extracutaneous features consistent with the genetic nature of
these disorders.
Table 1. Continued
MS–Musculoskeletal
1. Joint (89; 82)
2. Muscle (46; 61)
3. Skeletal (165; 137)
N–Nervous system
1. MR (148; 147)
2. Epilepsy (86; 99)
3. Neuropathy (31; 51)
4. Other (124; 140)
O–Ocular
1. Corneal/scleral disorder (including blue sclera) (31; 30)
2. Cataracts (44; 44)
3. Retinal disorder (19; 21)
4. Other/blindness (70; 82)
P–Pulmonary (58; 57)
R–Renal (52; 49)
T–Dental (45; 41)
U–Urogenital
1. External genitalia (39; 37)
2. Other (23; 22)
W–Malignancy (24; 23)
(a) Dermatological (cutaneous) phenotype subclass designation and
(b) Systemic (extracutaneous) phenotype subclass designation. Features
are shown.
Listed in parenthesis are the number of unique diseases expressing each
phenotype subclass and the number of unique genes that are associated
with each phenotype subclass, respectively.
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Figure 3. Skin findings associated with the genetic skin diseases. (a) Ranking
of cutaneous features by dermatological phenotype. The CGenDerm
phenotypic subclass is shown on the X-axis, and the absolute number of
disease units exhibiting each subclass is shown on the Y-axis. (b) Prevalence
of cutaneous features is shown in clusters of classes and subclasses.
(c) Distribution of cutaneous features among discrete skin disease units.
Most genetic skin diseases have a single dominant cutaneous feature;
however, there are many diseases with multiple distinct cutaneous features.
Number of cutaneous features is shown on the X-axis.
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To uncover the hidden phenotypic structure within the
disease space, we carried out a type 1 analysis (Figure 1),
focusing on one specific skin finding—cafe´-au-lait macules
(CALMs)—as an example. A total of 23 skin disease units
were found to have CALMs as a pigmented skin lesion and
were therefore further analyzed (Supplementary Table S2).
For these conditions, a ‘‘1’’ or ‘‘0’’ was assigned for the
presence or absence of 71 cutaneous and extracutaneous
features (Table 1). For replicative control, we arbitrarily
duplicated Turcot syndrome in the analysis. In the final
analysis, the subspace defined by the CALMs can be
represented as a 2471 matrix of 1s and 0s. Figure 5 shows
the similarity indexes based on feature clustering using
Raup–Crick metrics for the presence or absence of data
(http://folk.uio.no/ohammer/past). As expected, the dupli-
cates clustered very tightly (Turcot syndrome: nos. 17 and
18). Neurofibromatosis 1 (no. 10) and the Watson syndrome
(no. 19) also grouped closely; both are in fact associated with
genetic variants of the NF1 gene. Familial spinal neurofi-
bromatosis (no. 11) and neurofibromatosis 2 (no. 12) were
phenotypically more similar, given the predominance of
neural tumors as a feature, despite the distinct genetic loci
(NF1 and NF2, respectively); both were not very distantly
related to other neural tumor syndromes, such as familial
neuroblastoma (no. 9) and Turcot syndrome (nos. 17 and 18).
Finally, ataxia telangiectasia (no. 1), Nijmegan breakage
syndrome (no.13), and Bloom syndrome (no. 3) also clustered
closely, despite having distinct genetic loci (ATM, NBS1, and
BLM, respectively). One feature that links all three conditions
is chromosomal instability (Littlefield et al., 1981; Vijayalax-
mi et al., 1983; Jaspers et al., 1988), thereby raising the
possibility that the shared systemic manifestations reflect
multiorgan injury at the DNA repair level. Despite recogniz-
able limitations, these findings suggest that it is in fact possible
to cluster phenotypes using mathematical approaches.
Genotype assignation
Of the 560 unique GSDs (that is, those formally defined by a
unique OMIM entry), 543 are linked to known proteins (those
with GI (GenInfo Identifier) numbers); the remaining 17
diseases are associated with loci not defined by a protein GI
number. Overall, 84% of the 560 GSDs have a single gene
identified as the cause of the phenotype, 9% have two
different genes deemed responsible, and approximately 4%
have three or more known genes mutated (Figure 6a).
The genotypic space of GSDs involves 501 unique
protein-encoding genes. The majority (81.6%) of genes
associated with the genodermatoses were found mutated in
a single disease; 11.6%, 4%, and 2.8% were mutated in
two, three, and four or more unique diseases, respectively
(Figure 6b). It is interesting that the collagen, type VII, alpha-1
gene (COL7A1) was mutated most frequently, occurring in
nine distinct but related GSDs.
The mode of inheritance for many of the GSDs is known.
Of the 560 unique genodermatoses, autosomal recessive and
autosomal dominant were the most common modes of
inheritance, accounting for 46% and 37% of diseases,
respectively. X-linked recessive and X-linked dominant
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Figure 4. Extracutaneous features associated with genetic skin disease.
Extracutaneous features are shown in ascending order in terms of absolute
number of discrete skin disease units.
Central nervous
system tumor
cluster
Chromosomal
instability
cluster
NF1
cluster
15 514719108641133216121118179
0.96
0.88
0.8
0.72
0.64
0.56
0.48
0.4
0.32
Si
m
ila
rit
y
0 6 8 10 12 14 16 182 4
Figure 5. Cluster analysis of group 2B disorders (cafe´-au-lait macules). For
this analysis, the presence of a feature was coded as ‘‘1’’ and the absence as
‘‘0’’. Clustering was carried out with the PAST algorithm using Raup–Crick
similarity measures. 1. ATAXIA TELANGIECTASIA;
2. BANNAYAN–RILEY–RUVALCABA SYNDROME; 3. BLOOM SYNDROME;
4. FANCONI ANEMIA; 5. JOHANSON–BLIZZARD SYNDROME;
6. LEOPARD SYNDROME; 7. MCCUNE–ALBRIGHT SYNDROME;
8. MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; 9. NEUROBLASTOMA;
10. NEUROFIBROMATOSIS 1 (NF1); 11. NEUROFIBROMATOSIS, FAMILIAL
SPINAL; 12. NEUROFIBROMATOSIS, TYPE II; 13. NIJMEGEN BREAKAGE
SYNDROME; 14. RUBINSTEIN-TAYBI SYNDROME; 15. SEA-BLUE
HISTIOCYTE DISEASE; 16. TUBEROUS SCLEROSIS; 17. TURCOT
SYNDROME; 18. TURCOT SYNDROME; 19. WATSON SYNDROME.
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inheritance accounted for 4.2% and 1.9%, respectively.
Mitochondrial inheritance, sporadic, and unknown modes
together accounted for 11% of the inheritance patterns
(Figure 6c).
To explore the functional connections between GSD loci
(that is, type 2 analysis, Figure 1), we used the Ingenuity
Pathway Analysis software to map GSD genes onto specific
networks. Supplementary Figure S1 shows the intricate and
extensive relationships that exist among GSD loci. Figure 7
highlights two specific nodes for illustrative purposes. Germ-
line mutations of KRAS, BRAF, MAP2K1, or MAP2K2 all lead
to a similar profile of clinical findings, collectively defined as
the cardiofaciocutaneous syndrome (Figure 7a). This supports
the notion that interactive loci often produce overlapping
elemental features. On the other hand, mutations in HRAS,
PTPN11, and NF1 (Figure 7a) result in Costello syndrome,
Noonan /LEOPARD syndrome, and neurofibromatosis 1,
respectively. Finer phenotype resolution, however, reveals
that all three conditions harbor spotty pigmentation as a
cutaneous feature, thereby suggesting a possible mechanistic
link for these pigmented lesions. Analysis of the MITF node
shows another undescribed relationship between hearing loss
and depigmentation (Figure 7b). The Waardenburg syn-
dromes, characterized by hearing deficits and loss of
pigmentation, are associated with mutations in SNA12,
PAX3, MITF, and SOX10. Mutations in another set of genes
that interact with MITF—LOR, NOG, SOS, and GDF5—all
cause conditions with hearing loss, but no pigmentary
features. In contrast, other genes that regulate MITF (KIT
and POMC) or are direct targets of Mitf (TYR and TYRP1)
produce pure hypopigmentation.
DISCUSSION
In this study, we report on a general method for codifying and
manipulating phenotypes using GSD as a specific proof of
principle. There are several notable observations. More than
80% of GSDs are caused by a single gene defect, and more
than 80% of the gene defects cause only one condition; thus,
there is reasonable preservation of the one-gene-to-one-
disease association (although this is obviously biased by
OMIM’s focus on hereditary conditions). Nevertheless, these
estimates provide some sense of heterogeneity for GSD on a
global level. The number of oligogenic and polygenic
disorders can be expected to increase dramatically as
genomic efforts push toward resolving complex traits. It is
also possible, through phenotype deconvolution, to uncover
a hidden structure within the disease features space by
applying bioinformatics analytics, such as hierarchical
clustering, to disease features. In transforming a list of clinical
findings into discrete elements within the (f1, y, fN) space,
one can ‘‘digitize’’ the phenotype in much the same way that
the genome or transcriptome can be digitized by a
representation of single-nucleotide polymorphisms or oligo-
nucleotide transcripts, respectively. Our type 1 analysis of
CALM-related disorders uncovered several hidden groupings,
including those related to central nervous system tumors and
chromosomal instability. It is not surprising that familial
spinal neurofibromatosis (OMIM 162210) grouped more
closely with the central nervous system tumor–dominant
neurofibromatosis 2 (OMIM 101000) rather than with the
other NF1 conditions—neurofibromatosis 1 (OMIM 162220)
and Watson syndrome (OMIM 193520)—in which systemic
features play a more significant role. The robustness of
phenotype clustering is clearly dependent on the accuracy of
clinical observation. Our type 2 analysis using Ingenuity
Pathway Analysis software identified intricate relationships
among numerous GSD loci. Two well-populated nodes
involving RAS and MITF were particularly illustrative. In
one setting, disease units that show significant feature overlap
are often clinically defined as a single entity (for example,
cardiofaciocutaneous syndrome) and are caused by muta-
tions in loci that fall into a single pathway (KRAS–BRAF–-
MAPK). In other settings, as illustrated by the HRAS andMITF
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Figure 6. Genotypic analysis of genetic skin disease. (a) Each unique genetic
skin disease can be caused by mutations in multiple gene loci. (b) Mutations
in individual protein-coding loci can cause multiple unique genetic skin
diseases. (c) The mode of inheritance for genetic skin disease is variable.
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nodes, features themselves may segregate into functional
networks. The presence of spotty pigmentation along the
HRAS–NF1–PTPN11 axis recovers the known relationship
between RAS hyperactivation and pigment cell proliferation.
Moreover, the interaction between hypopigmentation and
hearing loss in the MITF node suggests that MITF may have
more general effects than melanocyte differentiation and
survival.
Finally, there are also seven GSDs caused by mutations in
four unique connexin proteins. Hyperkeratosis (skin phenotype
NF2* MAP2K2
MAP2K1
PTPN11*
PDGFRB
PDGFRA
GJA1
GJB2*
PKP1
KRT18
COL5A2*COL3A1*
NF1*
TAP1
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INSR*
NGF
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TSC1
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BRAF
PRNP
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EPOR
SNAI2
SOX10
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TYRP1*
PAX3*
SOST
LOR*
GDF5*
NOG
KIT
GATA1*
MITF*
Hearing loss
Pigmentation
Spotty pigmentation
Cardio-facio-cutaneous syndrome
Figure 7. Two networks identified by the Ingenuity Pathway Analysis program. (a) Interactions between components of the RAS network. Disorders such as the
cardiofaciocutaneous syndrome can be caused by germline variants in interacting proteins (shown in green). Alternatively, different disorders that fall into the
same pathway can lead to similar features. For instance, Costello syndrome (HRAS), LEOPARD (multiple lentigines, electrocardiographic abnormalities, ocular
hypertelorism, pulmonary stenosis, abnormalities of genitalia, growth retardation, and deafness) and Noonan syndromes (PTPN11), and neurofibromatosis 1
(NF1) are all characterized by spotty pigmentation as a cutaneous feature. In (b), previously undisclosed interactions between hearing loss and pigmentary
conditions map to the microphthalmia node. The Waardenburg syndromes, which are characterized by an absence of pigment cells and hearing loss, have been
associated with mutations in SNA12, SOX10, MITF, and PAX3. Loss of pigmentation is characteristic of individuals with KIT, pro-opiomelanocortin (POMC),
tyrosinase (TYR), and tyrosinase-related protein 1 (TYRP1) mutations. Finally, hearing deficits characterize individuals with NOG, SOST, GDF5, and LOR
mutations. Loci which are associated with multiple entries are labeled with an asterisk.
2634 Journal of Investigative Dermatology (2009), Volume 129
JD Feramisco et al.
Phenotypic and Genotypic Analyses of Genetic Skin Disease
number 1B) is found in all these diseases, and six of the
seven diseases also exhibit auditory deficits (systemic
phenotype A). In the entire database, there are 10 conditions
with both hyperkeratosis and auditory features out of 63
GSDs with hyperkeratosis and 93 GSDs with auditory
defects. Six of these cases are caused by mutations in
connexins, two by mutations in tumor protein p73–like (p63),
one by a synaptosomal-associated protein, 29-KD (SNAP29)
mutation, and one by a mutation in NAD(P)H steroid
dehydrogenase–like Protein (NSDHL). Although the associa-
tion between hearing and keratinocyte defects has been well
established for mutations in connexins (Rabionet et al., 2002;
Lai-Cheong et al., 2007) and has been vaguely suggested in
mutations in NSDHL (Bornholdt et al., 2005), little is known
about the role of p63 and SNAP29 in relation to these
phenotypes. When elemental features are carefully exam-
ined, well-designed analyses can become powerful engines
for generating hypotheses that to our knowledge are
previously unknown.
One obvious limitation of this study is in the accuracy and
potential incompleteness of the phenotyping and genotyping
data (George et al., 2008). In medicine, there is a tremendous
amount of subjectivity that is nearly impossible to eliminate
unless systematic reporting is undertaken. An ideal study
would use a database populated by prospectively annotated
phenotypes that includes thorough information for all organ
systems; unfortunately, such rich disease sets are not
available. Owing to the inherent complexities in disease
presentation within the clinical setting, phenotypic features are
often subject to misdiagnosis, inaccurate observations, reporting
bias, and data-extraction errors. We attempted to address these
issues by creating a priori categories and minimizing feature
convolution. For example, inaccuracies could arise if hyperpig-
mentation and telangiectasias are aggregated into poikiloderma.
Although OMIM contains a vast amount of data on disease
features, a more robust disease catalog would certainly yield
more powerful analyses.
In summary, phenotype deconvolution is, to our knowl-
edge, a previously unreported and potentially powerful
approach to discovering and cataloging relationships among
human diseases through elemental features. This is a
generalizable approach that is applicable to all diseases
without regard to any specific organ. Moreover, relationships
among the phenotypic, genotypic, and feature spaces can
generate hypotheses about biological mechanisms etiologi-
cally linked to human disease.
METHODS
OMIM search
As of May 2007, OMIM (http://www.ncbi.nlm.nih.gov/omim)
contained a total of 17,708 entries and described 2,114 diseases for
which a molecular basis is detailed. A search of OMIM on 1 May 2007
using the term ‘‘skin’’ yielded 2,319 entries representing distinct
disease entities. Of these, 826 entries represent a disease
that has both a phenotypic description and a known molecular
basis (‘‘#’’ tab on ‘‘Limits’’), and 313 entries represent diseases for
which a phenotypic description is available but that do not have a
known molecular basis. The remaining 1,180 entries correspond to
genes, genetic loci, or diseases with inadequate phenotypic descrip-
tion. We prepared our database from the 826 disease entries with a
known molecular basis and a primary cutaneous phenotype (Figure 2).
Phenotype deconvolution
For the purposes of this study, we defined a disease as one or more
disease units (a specific OMIM entry), as multiple genetic loci may
contribute to the same disease (that is, genetic heterogeneity) and
mutations in a single gene can cause more than one disease unit.
From a single disease (or disease unit), elemental features can be
extracted (for example, skin findings, neurological findings, and
cardiovascular findings) through a process akin to deconstructing
words into letters so as to organize language into tractable terms,
such as by alphabetical order or letter count. In broader terms,
disorders may be grouped into disease clusters (for example, diseases
that exhibit cornification as a strong feature would co-classify as a
cornification cluster) based either on shared features or on
hierarchical algorithms.
We defined a minimal set of phenotypic features, the combina-
tions of which cover all included genodermatoses, so that a
phenotypic manifestation of each skin disease can be represented
as a combination of skin and systemic features (Table 1). For
example, the group of pigmentation features includes hyper- and
hypopigmentation, CALMs, poikiloderma, and nevi (birthmarks and
moles). Most GSDs are characterized by more than one elemental
feature (average, 2.38 per disease).
Because two conditions can overlap in a large proportion of
features but result from variants at two different loci, we assigned an
entry for each composite phenotype if it corresponds to a unique
genetic etiology. For example, there are two gene ID numbers—
ID603324 (GJB3) and ID605425 (GJB4)—associated with a single
disease, erythrokeratoderma variabilis (OMIM 133200); we assigned
two separate entries for this single clinical entity. In time, subtle
differences between erythrokeratoderma variabilis disease units
caused by GJB3 and those caused by GJB4 may be appreciated.
The complete and detailed features of any and all OMIM skin entries
can be easily described using our classification system, which we
designated CGenDerm (Supplementary Table S1).
Feature-based cluster analysis
For the type 1 analysis (Figure 1), we assigned a ‘‘1’’ or ‘‘0’’ for the
presence or absence of features, respectively, for 71 independent
features, each representing a unique dimension in the multidimen-
sional feature space. Hierarchical clustering of this binary data was
carried out using the PAST data analysis package (University of Oslo,
Norway; http://folk.uio.no/ohammer/past) using the Raup–Crick
index.
Genotype assignation and analysis
We next cataloged and identified the sequence variants associated
with all diseases or disease units. Protein GI numbers were extracted
from the GenBank (Benson et al., 2008). The compilation of all
GSDs, along with their known etiological loci, is presented in the
CGenDerm database. Those having more than one known genetic
defect have multiple entries, listed once for each unique mutant
locus. For example, in Omenn syndrome, Recombination-activating
gene 1, Recombination-activating gene 2, and Artemis have been
shown to be mutated; therefore, Omenn syndrome has three
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separate entry lines in the table. The table also includes OMIM
disease ID, mutant gene name, OMIM mutant gene ID, protein GI
number for the defective gene, chromosomal loci of the defect,
disease inheritance pattern, detailed dermatological phenotype
description, and both the dermatological and systemic phenotypes
(in the key) based on our previously unreported classification
scheme.
Network analysis
Network relationships among GSD loci were identified and mapped
to nodes using the Ingenuity Pathway Analysis software (Ingenuity
Systems, Redwood City, CA; http://www.ingenuity.com). Statistical
methodologies for analysis are available on the website.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported in part by the American Cancer Society,
Massachusetts General Hospital (MGH) Institutional start-up funds, and
generous philanthropic donors to the MGH (all to H.T.).
SUPPLEMENTARY MATERIAL
Supplementary Information is linked to the online version of the paper at
www.nature.com/jid
REFERENCES
Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL (2008)
GenBank. Nucleic Acids Res 36:D25–30
Bornholdt D, Konig A, Happle R, Leveleki L, Bittar M, Danarti R et al. (2005)
Mutational spectrum of NSDHL in CHILD syndrome. J Med Genet
42:e17
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006)
Risk of myocardial infarction in patients with psoriasis. JAMA
296:1735–41
George RA, Smith TD, Callaghan S, Hardman L, Pierides C, Horaitis O et al.
(2008) General mutation databases: analysis and review. J Med Genet
45:65–70
Jaspers NG, Taalman RD, Baan C (1988) Patients with an inherited syndrome
characterized by immunodeficiency, microcephaly, and chromosomal
instability: genetic relationship to ataxia telangiectasia. Am J Hum Genet
42:66–73
Lai-Cheong JE, Arita K, McGrath JA (2007) Genetic diseases of junctions.
J Invest Dermatol 127:2713–25
Littlefield LG, Colyer SP, Joiner EE, DuFrain RJ, Frome E, Cohen MM (1981)
Chromosomal radiation sensitivity in ataxia telangiectasia
long-term lymphoblastoid cell lines. Cytogenet Cell Genet 31:
203–213
Rabionet R, Lopez-Bigas N, Arbones ML, Estivill X (2002) Connexin mutations
in hearing loss, dermatological and neurological disorders. Trends Mol
Med 8:205–12
Vijayalaxmi, Evans HJ, Ray JH, German J (1983) Bloom’s syndrome: evidence
for an increased mutation frequency in vivo. Science 221:851–3
2636 Journal of Investigative Dermatology (2009), Volume 129
JD Feramisco et al.
Phenotypic and Genotypic Analyses of Genetic Skin Disease
